Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT03225248 | Efficacy and Safety of UI05MSP015CT in Functional Dyspepsia | PHASE3 | COMPLETED | 143 | — | — | Nov 5, 2014 | Oct 12, 2015 | Jul 21, 2017 | - | — |
Change of symptom score of functional dyspepsia was evaluated by symptom-specific questionnaire.
| Arm | Type | Description |
|---|---|---|
| UI05MSP015CT | EXPERIMENTAL | UI05MSP015CT and Placebo of Gasmotin |
| Gasmotin | ACTIVE_COMPARATOR | Placebo of UI05MSP015CT and Gasmotin |
| Name | Type | Description |
|---|---|---|
| UI05MSP015CT | DRUG | UI05MSP015CT and Placebo of Gasmotin |
| Gasmotin | DRUG | Placebo of UI05MSP015CT and Gasmotin |
Inclusion Criteria: 1. Age \>19 years 2. Diagnosis of functional dyspepsia meeting Rome III criteria 3. At least three moderate or severe symptoms included in the Symptom Score 4. No structural lesions of upper gastrointestinal tract Exclusion Criteria: 1. History of dyspepsia unrelated to functi...